

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL HOLDINGS FOR THE THREE MONTHS ENDED 31 MARCH 2024 IN RELATION TO ISSUANCES OF MEDIUM TERM NOTES AND CORPORATE BONDS IN THE PRC

Reference is made to: (i) the announcement dated 23 June 2021 in relation to, among others, the completion of the issuance of the first tranche of medium term notes for the year of 2021 by China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly owned subsidiary of the Company; and (ii) the announcement dated 21 January 2022 in relation to, among others, the completion of the public issuance of the 2022 first tranche corporate bonds in the PRC by CR Pharmaceutical Holdings (the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

In accordance with the relevant rules and regulations in the PRC and in connection with its issuances of medium term notes and corporate bonds in the PRC, CR Pharmaceutical Holdings has published its audited report for the year ended 31 December 2023 and unaudited financial statements for the three months ended 31 March 2024 on the website of Beijing Financial Assets Exchange and has published its audited report for the year ended 31 December 2023 on the website of the Shanghai Stock Exchange.

The unaudited financial statements of CR Pharmaceutical Holdings for the three months ended 31 March 2024 (the “**Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings**”) are enclosed to this announcement for the Company’s shareholders’ information only. The Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings were prepared in Chinese and have been translated for publication in English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail. In addition, the Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company’s auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Holdings only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

PRC, 30 April 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
BALANCE SHEET IN ACCORDANCE WITH THE PRC STANDARDS
MARCH 2024

Adjusted to denominated currency

Unit: RMB1

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	2,638,949,420.00	2,337,855,541.84	Short-term borrowings	195,673.65	-
Held-for-trading financial assets	307,878.31	200,307,878.31	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	-	-
Notes receivable	-	-	Including: Notes payable	-	-
Accounts receivable	-	-	Accounts payable	-	-
Financing receivables	-	-	Receipts in advance	-	-
Prepayment	1,430.49	-	Contract liabilities	-	-
Other receivables	14,665,782,060.29	17,189,862,546.62	Staff remuneration payable	16,477,505.05	41,083,867.49
Including: Interest receivable	-	-	Including: Wages payable	-	-
Dividends receivable	5,766,748,449.32	5,766,748,449.32	Benefits payable	532.51	-
Inventory	-	-	Taxation payable	7,042,126.29	2,824,395.94
Including: Raw materials	-	-	Including: Tax payable	7,042,126.29	2,824,395.94
Goods in stock (finished products)	-	-	Other payables	-	-
Contract assets	-	-		1,643,355,968.55	2,967,935,929.74
Assets held for sale	-	-	Including: Interest payable	36,576,944.45	7,775,895.87
Non-current assets due within one year	-	-	Dividends payable	800,000,000.00	800,000,000.00
Other current assets	-	24,047,882.42	Insurance contract liabilities	-	-
			Liabilities held for sale	-	-
			Non-current liabilities due within one year	8,621,981,750.12	3,606,724,778.43
			Other current liabilities	-	-
Total current assets	17,305,040,789.09	19,752,073,849.19	Total current liabilities	10,289,053,023.66	6,618,568,971.60
Non-current assets:			Non-current liabilities:		
Other debt investments	-	-	Long-term borrowings	880,000,000.00	7,236,890,000.00
Debt investments	-	-	Bonds payable	2,289,220,935.11	2,000,000,000.00
Long-term receivables	10,000,000.00	-	Long-term payables	-	-
Other equity instruments investments	-	-	Including: Long-term payables	-	-
Long-term equity investments	15,869,355,559.08	15,839,112,046.97	Special payables	-	-
Investment properties	-	-	Long-term employee remuneration payable	332,150,000.00	304,600,000.00
Other non-current financial assets	-	-	Deferred revenue	-	-
Fixed assets	2,867,663.67	2,932,595.58	Estimated liabilities	-	-
Including: Disposal of fixed assets	3,532.35	3,532.35	Deferred income tax liabilities	2,797,587.80	2,797,587.80
Right-of-use assets	11,061,361.81	11,061,361.81	Lease liabilities	12,202,086.10	676,818.20
Construction in progress	-	-	Other non-current liabilities	-	-
Including: Construction materials	-	-	Including: Special reserve	-	-
Biological assets for production	-	-	Total non-current liabilities	3,516,370,609.01	9,544,964,406.00
Oil and gas assets	-	-	Total liabilities	13,805,423,632.67	16,163,533,377.60
Intangible assets	-	-	Owners' equity (or shareholders' equity):		
Including: Land use right	-	-	Paid-in capital (equity)	18,507,000,000.00	18,507,000,000.00
Development expenses	-	-	State-owned capital	-	-
Goodwill	-	-	Collective capital	-	-
Long-term deferred expenses	-	-	Legal person capital	-	-
Deferred income tax assets	3,050,521.52	3,050,521.52	Including: State-owned legal person capital	-	-
Other non-current assets	-	10,000,798.40	Collectively-owned legal person capital	-	-
Including: Contract assets	-	-	Individual	-	-
			Foreign capital	-	-
			Capital surplus	34,472,792.11	34,472,792.11
			Less: treasury shares	-	-
			Other comprehensive income	31,620,416.58	31,620,416.58
			Including: Differences on translation of foreign currency	-	-
			Surplus reserves	894,910,348.50	894,910,348.50
Total non-current assets	15,896,335,106.08	15,866,157,324.28	Special reserves	-	-
			Undistributed profits	(72,051,294.69)	(13,305,761.32)
			Total equity attributable to owners of the parent company	19,395,952,262.50	19,454,697,795.87
			Minority interests	-	-
			Total owners' equity	19,395,952,262.50	19,454,697,795.87
Total assets	33,201,375,895.17	35,618,231,173.47	Total liabilities and owners' equity	33,201,375,895.17	35,618,231,173.47

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF PROFIT OR LOSS IN ACCORDANCE WITH THE PRC STANDARDS
MARCH 2024

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Operating revenue	–	–
Including: Revenue from principal businesses	–	–
Revenue from other businesses	–	–
II. Operating costs	–	–
Including: Costs for principal businesses	–	–
Costs for other businesses	–	–
Tax and surcharge	1,089,693.55	10,063.48
Selling expenses	–	–
Management expenses	26,006,294.97	33,039,719.44
Including: Entertainment expenses	52,131.33	43,211.14
Research and development expenses	3,478,183.48	264,150.94
Finance costs	57,458,025.28	(61,415,464.07)
Including: Interest expenses	89,769,281.91	87,399,877.13
Interest income	34,299,939.12	20,695,013.46
Net loss from exchange (net gain is represented by “–”)	178,158.23	(128,122,435.24)
Other revenue	198,267.66	177,799.90
Gain from investment (loss is represented by “–”)	30,395,594.31	71,853,109.03
Including: Gains from investment in associates and joint ventures	30,243,512.11	71,853,109.03
Net gains from hedging exposure (loss is represented by “–”)	–	–

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
Add: Gains from changes in fair values (loss is represented by “—”)	—	178,888.92
Impairment losses of assets	—	—
Loss on credit impairment	—	—
Gains from disposal of assets	—	—
III. Operating profits (loss is represented by “—”)	(57,438,335.31)	100,311,328.06
Add: Non-operating income	339,017.44	—
Including: Gains from exchanging non-monetary assets	—	—
Government subsidies	—	—
Less: Non-operating expenses	1,500,000.00	—
Including: Loss on exchanging non-monetary assets	—	—
IV. Total profits (total loss is represented by “—”)	(58,599,317.87)	100,311,328.06
Less: Income tax expenses	—	—
V. Net profits (net loss is represented by “—”)	(58,599,317.87)	100,311,328.06
Including: Net profits of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	(58,599,317.87)	100,311,328.06
Gains and losses of minority interests	—	—
Profit attributable to holders of perpetual capital instruments	—	—

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
VI. Other comprehensive income, net of tax	–	–
(I) Other comprehensive income that cannot be reclassified into profit or loss	–	–
Changes arising from remeasurement of defined benefit plan	–	–
Other comprehensive income that cannot be reclassified into profit or loss under the equity method	–	–
Changes in fair value of other equity instrument investments	–	–
(II) Other comprehensive income that may be reclassified to profit or loss	–	–
Other comprehensive income that may be reclassified to profit or loss under equity method	–	–
Changes in fair value of other debt investments	–	–
Amount included in other comprehensive income on reclassification of financial assets	–	–
Provision for credit impairment of other debt investment	–	–
Revaluation of fixed assets	–	–
Cash flows hedging reserve	–	–
Differences arising from translation of foreign currency	–	–
Others	–	–

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
VII. Total comprehensive income	(58,599,317.87)	100,311,328.06
VIII. Earnings per share:	–	–
Basic earnings per share	–	–
Diluted earnings per share	–	–
Add: Undistributed profit at the beginning of the year	(13,451,976.82)	139,719,503.05
Changes in accounting policies	–	–
Losses covered by surplus reserve	–	–
Other adjustment factors	–	–
IX. Distributable profit	(72,051,294.69)	240,030,831.11
Less: Appropriation of statutory surplus reserve	–	–
Appropriation for staff bonuses and benefit funds	–	–
Appropriation for reserve funds	–	–
Appropriation for company development funds	–	–
Others	–	–
X. Distributable profit attributable to investors	(72,051,294.69)	240,030,831.11
Preference shares dividends payable	–	–
Appropriation of discretionary surplus reserve	–	–
Ordinary shares dividends payable	–	–
Ordinary shares dividends converted to equity	–	–
Others	–	–
XI. Undistributed profit	(72,051,294.69)	240,030,831.11

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF CASH FLOWS IN ACCORDANCE WITH THE PRC
STANDARDS MARCH 2024

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	–	–
Refund of taxes and levies	–	188,467.89
Cash received relating to other operating activities	3,005,004,514.24	4,118,145.94
Sub-total of cash inflows from operating activities	3,005,004,514.24	4,306,613.83
Cash paid for goods purchased and services received	–	–
Cash paid to and for employees	45,905,959.34	38,004,027.23
Payments of all types of taxes	1,089,693.55	92,947.09
Cash payments relating to other operating activities	1,040,954,854.73	71,866,899.53
Sub-total of cash outflows from operating activities	1,087,950,507.62	109,963,873.85
Net cash flow from operating activities	1,917,054,006.62	(105,657,260.02)
II. Cash Flow From Investing Activities:		
Cash received from investment recovery	3,985,000,000.00	4,720,000,000.00
Cash received from returns on investments	13,580,680.07	–
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	–	–
Net cash received from disposals of subsidiaries and other operating units	–	–
Cash received relating to other investing activities	–	–
Sub-total of cash inflows from investing activities	3,998,580,680.07	4,720,000,000.00

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
Cash paid to acquire fixed assets, intangible assets and other long-term assets	59,440.00	–
Cash paid for investments	3,200,000,000.00	4,723,660,000.00
Net cash paid for acquisition of subsidiaries and other operational units	–	–
Cash payments relating to other investing activities	–	–
Sub-total of cash outflows from investing activities	3,200,059,440.00	4,723,660,000.00
Net cash flow from investing activities	798,521,240.07	(3,660,000.00)
III. Cash flow from financing activities:		
Cash received from capital contribution	–	–
Including: Cash received by subsidiaries from investments of minority shareholders	–	–
Cash received from borrowings	–	4,500,000,000.00
Cash received from issuance of bonds	–	–
Cash payments relating to other financing activities	683,922,590.47	990,287,241.79
Sub-total of cash inflows from financing activities	683,922,590.47	5,490,287,241.79
Cash payments for debts settlement	960,000,000.00	4,443,800,000.00
Cash payments for distribution of dividends, profits, or interest expenses	101,268,304.43	95,032,371.12
Including: Dividends and profits paid by subsidiaries to minority shareholders	–	–
Cash payments relating to other financing activities	2,037,136,677.64	793,173,434.00
Sub-total of cash outflows from financing activities	3,098,404,982.07	5,332,005,805.12
Net cash flow from financing activities	(2,414,482,391.60)	158,281,436.67
IV. Effect of foreign exchange rate changes on cash and cash equivalents	1.26	(36.67)
V. Net increase in cash and cash equivalents	301,092,856.35	48,964,139.98
Add: Opening balance of cash and cash equivalent	2,337,855,765.25	707,909,890.75
VI. Closing balance of cash and cash equivalents	2,638,948,621.60	756,874,030.73

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
(CONSOLIDATED) BALANCE SHEET IN ACCORDANCE WITH
THE PRC STANDARDS MARCH 2024

Adjusted to denominated currency

Unit: RMB1

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	32,742,394,551.38	31,519,847,175.49	Short-term borrowings	50,873,505,932.25	41,760,881,868.23
Held-for-trading financial assets	7,878,387,559.77	7,574,062,344.05	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	58,372,991,086.80	55,032,304,738.18
Notes receivable	1,120,422,566.31	993,646,232.47	Including: Notes payable	15,271,042,248.07	15,810,964,629.79
Accounts receivable	75,863,356,364.94	67,728,531,209.10	Accounts payable	43,101,948,838.73	39,221,340,108.39
Financing receivables	30,771,720,128.18	27,035,215,652.33	Receipts in advance	822,381.24	1,154,184.25
Prepayment	5,988,619,557.84	4,790,694,431.30	Contract liabilities	5,188,135,561.24	4,022,963,964.65
Other receivables	6,957,990,840.12	5,845,747,405.00	Staff remuneration payable	2,699,722,215.43	3,398,994,944.77
Including: Interest receivable	1,838,668.90	1,580,238.93	Including: Wages payable	789,403,113.04	3,073,306,379.88
Dividends receivable	0.00	0.00	Benefits payable	486,417.92	19,233,924.73
Inventory	34,992,951,662.63	31,800,158,742.41	Taxation payable	1,555,102,667.69	1,494,725,617.46
Including: Raw materials	2,944,608,104.55	2,556,263,564.85	Including: Tax payable	1,428,171,318.10	1,464,441,971.01
Goods in stock (finished products)	29,183,849,329.05	25,477,592,348.25	Other payables	26,287,270,513.80	26,611,902,773.86
Contract assets	1,003,285.39	2,447,606.72	Including: Interest payable	42,788,522.97	13,836,576.68
Assets held for sale	38,563,956.10	38,563,956.10	Dividends payable	4,579,923,736.12	5,921,546,995.27
Non-current assets due within one year	86,501,500.56	8,744,965.56	Insurance contract liabilities	-	-
Other current assets	1,352,497,412.03	1,459,520,163.48	Liabilities held for sale	-	-
			Non-current liabilities due within one year	9,139,957,221.37	4,460,602,251.45
			Other current liabilities	569,851,472.67	659,335,487.91
Total current assets	197,794,409,385.24	178,797,179,884.01	Total current liabilities	154,687,359,052.49	137,442,865,830.76
Non-current assets:			Non-current liabilities:		
Other debt investments			Long-term borrowings	7,872,800,282.10	11,093,432,363.51
Debt investments	122,076,020.17	119,020,317.84	Bonds payable	4,097,812,981.69	3,999,046,121.63
Long-term receivables	731,998,028.86	685,222,308.33	Long-term payables	324,282,862.29	293,497,856.45
Other equity instruments investments	71,804,172.38	71,804,172.38	Including: Long-term payables	22,000,000.00	22,000,000.00
Long-term equity investments	5,452,180,222.19	5,107,550,226.12	Special payables	302,282,862.29	271,497,856.45
Investment properties	337,025,065.93	341,622,922.05	Long-term employee remuneration payable	791,165,297.94	761,698,147.19
Other non-current financial assets	553,565,955.73	775,641,249.98	Deferred revenue	829,913,305.42	788,580,545.58
Fixed assets	17,640,185,366.07	17,902,465,319.18	Estimated liabilities	55,671,336.51	54,169,201.13
Including: Disposal of fixed assets	9,408,028.72	6,314,079.25	Deferred income tax liabilities	1,538,088,424.30	1,496,039,010.98
Right-of-use assets	1,221,241,628.62	1,254,262,956.75	Lease liabilities	812,932,366.11	826,695,026.11
Construction in progress	1,578,031,789.87	1,405,422,617.77	Other non-current liabilities	29,897,725.29	30,457,290.34
Including: Construction materials	-	-	Including: Special reserve		
Biological assets for production	13,235,107.66	12,877,508.60	Total non-current liabilities	16,352,564,581.65	19,343,615,562.92
Oil and gas assets	-	-	Total liabilities	171,039,923,634.14	156,786,481,393.68
Intangible assets	10,205,061,769.21	10,293,514,191.83	Owners' equity (or shareholders' equity):		
Including: Land use right	3,596,442,210.79	3,561,565,734.99	Paid-in capital (equity)	18,507,000,000.00	18,507,000,000.00
Development expenses	1,437,851,273.74	1,468,203,190.50	State-owned capital		
Goodwill	21,454,280,037.11	21,454,280,037.09	Collective capital		
Long-term deferred expenses	400,691,834.78	415,376,572.56	Legal person capital		
Deferred income tax assets	1,808,129,712.78	1,742,650,193.75	Including: State-owned legal person capital		
Other non-current assets	2,515,486,338.63	2,515,815,185.21	Collectively-owned legal person capital		
Including: Contract assets	18,144,171.84	20,348,090.24	Individual's capital		
			Foreign capital		

			Capital surplus	219,252,074.89	604,455,027.36
			Less: treasury shares	0.01	-
			Other comprehensive income	53,277,089.65	60,309,057.74
			Including: Differences on translation of foreign currency	45,528,691.14	45,577,480.25
			Surplus reserves	669,824,912.50	654,700,528.34
Total non-current assets	65,542,844,323.73	65,565,728,969.94	Special reserves	3,400,832.24	2,911,219.26
			Undistributed profits	15,153,225,963.23	13,919,036,328.65
			Total equity attributable to owners of the parent company	34,605,980,872.50	33,748,412,161.35
			Minority interests	57,691,349,202.33	53,828,015,298.92
			Total owners' equity	92,297,330,074.83	87,576,427,460.27
Total assets	263,337,253,708.97	244,362,908,853.95	Total liabilities and owners' equity	263,337,253,708.97	244,362,908,853.95

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CONSOLIDATED)
STATEMENT OF PROFIT OR LOSS IN ACCORDANCE WITH THE PRC STANDARDS
MARCH 2024

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Operating revenue	66,159,599,039.23	60,549,929,362.59
Including: Revenue from principal businesses	65,762,455,650.93	60,029,852,186.95
Revenue from other businesses	397,143,388.30	520,077,175.65
II. Operating costs	55,032,920,892.14	50,251,436,013.89
Including: Costs for principal businesses	54,856,083,265.81	49,965,586,141.08
Costs for other businesses	176,837,626.33	285,849,872.81
Tax and surcharge	280,360,430.79	248,033,819.21
Selling expenses	4,703,414,620.25	4,426,123,806.66
Management expenses	1,390,872,573.23	1,328,847,312.68
Including: Entertainment expenses	18,478,712.36	20,076,392.41
Research and development expenses	445,919,537.82	371,171,483.28
Finance costs	345,622,038.88	376,703,357.22
Including: Interest expenses	473,323,257.95	569,935,171.62
Interest income	156,450,148.29	96,392,668.40
Net Loss from exchange (net gain is represented by “—”)	(1,001,646.60)	(128,858,621.96)
Other revenue	98,087,023.94	79,140,305.25
Gain from investment (loss is represented by “—”)	73,652,263.75	100,515,975.02
Including: Gains from investment in associates and joint ventures	108,824,066.42	121,926,290.29

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
Net gains from hedging exposure (loss is represented by “—”)	—	—
Add: gains from changes in fair values (loss is represented by “—”)	23,766,028.54	51,533,760.24
Impairment losses of assets	26,924,573.76	23,237,597.07
Loss on credit impairment	424,310,013.28	280,081,221.32
Gains from disposal of assets	2,039,301.54	4,417,615.61
III. Operating profits (loss is represented by “—”)	3,706,798,976.84	3,479,902,407.39
Add: Non-operating income	43,338,840.36	13,541,640.02
Including: Gains from exchanging non-monetary assets	—	—
Government subsidies	260,740.47	160,500.00
Less: Non-operating expenses	19,516,658.02	12,549,034.74
Including: Loss on exchanging non-monetary assets	—	—
IV. Total profits (total loss is represented by “—”)	3,730,621,159.18	3,480,895,012.67
Less: Income tax expenses	800,614,069.27	700,072,899.57
V. Net profits (net loss is represented by “—”)	2,930,007,089.91	2,780,822,113.10
Including: Net gains of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	1,235,083,544.10	1,263,188,228.44
Gains and losses of minority interests	1,662,973,545.81	1,485,683,884.66
Profit attributable to holders of perpetual capital instruments	31,950,000.00	31,950,000.00

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
VI. Other comprehensive income, net of tax	(271,680.44)	(4,229,839.78)
(I) Other comprehensive income that cannot be reclassified into profit and loss	–	–
Changes arising from remeasurement of defined benefit plan	–	–
Other comprehensive income that cannot be reclassified into profit or loss under the equity method	–	–
Changes in fair value of other equity instrument investments	–	–
(II) Other comprehensive income that may be reclassified to profit or loss	(271,680.44)	(4,229,839.78)
Other comprehensive income that may be reclassified to profit or loss under equity method	93,075.28	–
Change in fair value of other debt investments	264.35	–
Amount included in other comprehensive income on reclassification of financial assets	–	–
Provision for credit impairment of other debt investment	–	–
Revaluation of fixed assets	–	–
Cash flows hedging reserve	–	–
Exchange differences arising from translation of foreign currency	(365,020.07)	(4,229,839.78)
Others	–	–
VII. Total comprehensive income	2,929,735,409.47	2,776,592,273.32

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
VIII. Earnings per share:	–	–
Basic earnings per share	–	–
Diluted earnings per share	–	–
Add: undistributed profit at the beginning of the year	13,918,142,419.12	11,950,022,426.56
Changes in accounting policies	–	23,511.00
Losses covered by surplus reserve	–	–
Other adjustment factors	–	–
IX. Distributable profit	15,153,225,963.23	13,213,234,166.00
Less: Appropriation of statutory surplus reserve	–	–
Appropriation for staff bonuses and benefit funds	–	–
Appropriation for reserve funds	–	–
Appropriation for company development funds	–	–
Others	–	–
X. Distributable profit attributable to investors	15,153,225,963.23	13,213,234,166.00
Preference shares dividends payable		
Appropriation of discretionary surplus reserve	–	–
Ordinary shares dividends payable	–	–
Ordinary shares dividends converted to equity	–	–
Others	–	16,294,500.00
XI. Undistributed profit	15,153,225,963.23	13,229,528,666.00

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
(CONSOLIDATED) STATEMENT OF CASH FLOWS IN ACCORDANCE WITH
THE PRC STANDARDS
MARCH 2024**

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
I. Cash flow from operating activities:		
Cash received from the sales of goods and the rendering of services	60,817,181,529.39	54,344,401,484.28
Refund of taxes and levies	10,444,182.50	89,961,797.00
Cash received relating to other operating activities	2,882,660,557.94	3,211,013,993.66
Sub-total of cash inflows from operating activities	63,710,286,269.83	57,645,377,274.94
Cash paid for goods purchased and services received	56,590,335,983.08	51,547,385,718.49
Cash paid to and for employees	3,924,974,923.09	3,495,379,012.33
Payments of all types of taxes	2,541,995,021.27	2,375,112,076.13
Cash payments relating to other operating activities	5,749,633,764.00	6,397,763,580.13
Sub-total of cash outflows from operating activities	68,806,939,691.45	63,815,640,387.08
Net cash flow from operating activities	(5,096,653,421.62)	(6,170,263,112.14)
II. Cash flow from investing activities:		
Cash received from investment recovery	3,998,926,034.14	2,634,654,230.74
Cash received from returns on investments	100,702,091.98	19,970,430.90
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	6,234,103.45	3,240,373.46
Net cash received from disposals of subsidiaries and other operating units	–	2,897,455.61
Cash received relating to other investing activities	11,622,895.29	3,250,726.48
Sub-total of cash inflows from investing activities	4,117,485,124.86	2,664,013,217.19

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
Cash paid to acquire fixed assets, intangible assets and other long-term assets	418,112,138.99	528,663,079.82
Cash paid for investments	4,798,418,144.89	3,080,033,383.51
Net cash paid for acquisition of subsidiaries and other operating units	65,578,194.53	(1,243,235,926.12)
Cash payments relating to other investing activities	1,016,368.83	79,950.00
Sub-total of cash outflows from investing activities	5,283,124,847.24	2,365,540,487.21
Net cash flow from investing activities	(1,165,639,722.38)	298,472,729.98
III. Cash flow from financing activities:		
Cash received from capital contribution	2,035,550,000.00	277,050,000.00
Including: Cash received by subsidiaries from investments of minority shareholders	-	-
Cash received from borrowings	25,207,220,049.68	29,946,040,860.48
Cash received from issuance of bonds	-	-
Cash received relating to other financing activities	3,948,334,024.84	5,888,824,175.31
Sub-total of cash inflows from financing activities	31,191,104,074.52	36,111,915,035.79
Cash payments for debts settlement	17,334,199,085.43	21,726,218,902.61
Cash payments for distribution of dividends, profits, or interest expenses	1,530,144,012.81	626,500,035.98
Including: Dividends and profits paid by subsidiaries to minority shareholders	3,200,000.00	-
Cash payments relating to other financing activities	4,045,641,538.97	4,171,384,075.55
Sub-total of cash outflows from financing activities	22,909,984,637.21	26,524,103,014.14
Net cash flow from financing activities	8,281,119,437.31	9,587,812,021.65
IV. Effect of foreign exchange rate changes on cash and cash equivalents	294,988.64	(1,873,772.53)
V. Net increase in cash and cash equivalents	2,019,121,281.95	3,714,147,866.96

Item	Accumulated amount for the year	Accumulated amount for the corresponding period of last year
Add: Opening balance of cash and cash equivalents	24,508,233,747.07	15,139,972,048.18
VI. Closing balance of cash and cash equivalents	26,527,355,029.02	18,854,119,915.14